|
Synonyms: MET-097 | MET-097i | MET097 | PF'3944 | PF-08653944 | PF08653944
Compound class:
Peptide
Comment: Berobenatide (PF-08653944, formerly MET097) is an ultra-long-acting GLP-1 receptor agonist. Structurally, berobenatide is an exendin-4 analogue that is modified for extended circulating half-life (~15.5 days).
|
| No information available. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT07595549 | A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity | Phase 3 Interventional | Pfizer | The VESPER-6 study | |
| NCT07575932 | A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1) | Phase 2 Interventional | Pfizer | The SOLIS-1 study | |
| NCT07400653 | A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | Phase 3 Interventional | Pfizer | The VESPER-5 study | |
| NCT07311850 | Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity | Phase 3 Interventional | Pfizer | The VESPER-4 study | |